Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
Status:
Recruiting
Trial end date:
2025-12-18
Target enrollment:
Participant gender:
Summary
This is an early phase study to assess the safety and tolerability of ONO-4685 in patients
with psoriasis. In addition, the study will assess how the drug is distributed and eliminated
by the body (pharmacokinetics) and how the drug affects the body (pharmacodynamics). This
will be done by measuring the amount of drug in the blood and measuring other markers in the
body that might have been affected by ONO-4685. The study will also look at preliminary
information on whether ONO-4685 might be effective in treating psoriasis.
The study will be split into three parts. Part A will assess a single dose of ONO-4685 in
small groups of patients, each group planned to receive a higher dose than the last group. In
Part B, patients will receive multiple doses of ONO-4685 over a period of 4 weeks. Based on
information gathered in Part B, a dose and frequency of dose will be selected for Part C